On-table monitoring of prostate MRI could enable tailored utilisation of gadolinium contrast
Question Default use of gadolinium contrast in prostate MRI is not always of clinical benefit and has associated side effects and healthcare costs. Findings On-table monitoring avoided the use of gadolinium in 75.8% of patients, reducing associated costs whilst maintaining clinically significant cancer detection, and diagnostic accuracy and improving reader confidence. Clinical relevance On-table monitoring offers personalised patient protocolling with a significant reduction in the use of gadolinium and its associated side effects and costs, potentially maximising the advantages of both multiparametric and biparametric prostate MRI.
Authors
- Tristan Barrett (ORCID: https://orcid.org/0000-0002-1180-1474)
- Bruno Carmo
- Christopher J. Shepherd (ORCID: https://orcid.org/0000-0001-8540-815X)
- Iztok Caglič (ORCID: https://orcid.org/0000-0002-3432-3540)
- Tom Syer (ORCID: https://orcid.org/0000-0001-9594-9638)
- Brooke Lawson (ORCID: https://orcid.org/0009-0005-1664-5414)
- Wellington Chishaya
- Nimalam Sanmugalingam
Institutions
- University of Cambridge (GB)
- Cambridge University Hospitals NHS Foundation Trust (GB)
- Addenbrooke's Hospital (GB)
Publication Details
- Journal
- European Radiology
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1007/s00330-025-11479-3
- Citations
- 5
- Primary Topic
- Prostate Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- Cancer Research UK
- Prostate Cancer UK
- Engineering and Physical Sciences Research Council
- NIHR Cambridge Biomedical Research Centre